BeVigilant™ OraFusion™ System**

Granted FDA Breakthrough Device Designation

The BeVigilant™ OraFusion™ System** is Not Available For Sale in the U.S.

The BeVigilant™ OraFusion™ System** identifies the presence of biomarkers associated with oral cancer in 15 minutes or less.

BeVigilant™ OraFusion™ System with Cassette Open

BeVigilant™ OraFusion™ System**

With the BeVigilant™ OraFusion™ System, clinicians can get a simple and accurate* assessment to aid in the early detection of oral cancer. The platform provides a semi-quantitative result at the point–of–care, reporting low, moderate or elevated levels of risk associated with oral cancer. Learn how it benefits dentists and their patients:

BeVigilant™ OraFusion™ Test Output: Biomarkers + Clinical Risk Factors

Moderate Risk App Chart

How the BeVigilant™ OraFusion™ System** Works

BeVigilant™ OraFusion™ System is an easy-to-use, accurate*, semi-quantitative tool for frontline healthcare clinicians assessing potentially at-risk patients for oral cancer.
The BeVigilant™ Reader is an advanced immunochromatography reader which captures the test data and provides the results during the patient’s visit.

Created to improve outcomes through earlier intervention, the BeVigilant™ OraFusion™ System** is

Check Mark Icon


Using multiple biomarkers in conjunction with clinical risk factors provides an accurate risk assessment

Check Mark Icon


Simple saliva test

Check Mark Icon


Results in just 15 minutes or less

The BeVigilant™ OraFusion™ System is patent pending and available in select markets outside the United States. Interested in learning more about the technology’s availability in your market?

Schedule a demo to discover if the BeVigilant OraFusion System is right for your practice.

*Clinical Data on File